These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20166202)

  • 1. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
    Houghton PJ; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wu J; Smith MA
    Pediatr Blood Cancer; 2010 Jul; 54(7):921-6. PubMed ID: 20166202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1190-7. PubMed ID: 18260118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Maris JM; Keir ST; Morton CL; Wu J; Wozniak AW; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2012 May; 58(5):729-35. PubMed ID: 21630428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2011 Apr; 56(4):595-603. PubMed ID: 21298745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
    Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
    Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
    Smith MA; Morton CL; Phelps DA; Kolb EA; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):34-41. PubMed ID: 18260120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.
    Maris JM; Courtright J; Houghton PJ; Morton CL; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Jul; 51(1):42-8. PubMed ID: 18293383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kolb EA; Gorlick R; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Apr; 50(4):799-805. PubMed ID: 17635004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
    Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
    Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
    Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
    Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
    Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms.
    Zamykal M; Martens T; Matschke J; Günther HS; Kathagen A; Schulte A; Peters R; Westphal M; Lamszus K
    Neuro Oncol; 2015 Aug; 17(8):1076-85. PubMed ID: 25543125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.
    Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gorlick R; Kolb EA; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2012 Jun; 58(6):916-23. PubMed ID: 21584937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial testing of cisplatin by the pediatric preclinical testing program.
    Tajbakhsh M; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB
    Pediatr Blood Cancer; 2008 May; 50(5):992-1000. PubMed ID: 17554786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
    Gorlick R; Kolb EA; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock R; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA
    Pediatr Blood Cancer; 2012 Dec; 59(7):1266-74. PubMed ID: 22315240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
    Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.